Cite

HARVARD Citation

    Fontanella, C. et al. (2022). Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach. Critical reviews in oncology/hematology. p. . [Online]. 
  
Back to record